ViCentra
ViCentra is a Utrecht-based medical device company that designs and commercializes the Kaleido compact, customizable insulin patch pump system for adults with Type 1 diabetes, integrating Diabeloop hybrid closed-loop algorithms and Dexcom CGM, sold via healthcare-provider prescriptions across Germany, Netherlands, and France with U.S. entry pending FDA approval.
- Company typePrivate
- Founded2013
- HeadquartersUtrecht, Netherlands
- Headcount101–250
- GTM typeB2C
- OfferingHardware or Manufacturing
What ViCentra does
ViCentra B.V. is a Utrecht, Netherlands-based medical device company founded in 2013 that designs, manufactures, and commercializes the Kaleido insulin patch pump system for adults with Type 1 diabetes. The flagship Kaleido pump is a compact (50x35x12.5mm, 19g), reusable, IP68-rated (1.5m for 1 hour) device available in 10 color combinations, with a 4-year warranty and a dual-wear design that supports both on-body patch and pocket wear via 5cm or 30cm tubing. The platform integrates with Diabeloop's DBLG1 and DBLG2 self-learning hybrid closed-loop algorithms and Dexcom G6/G7 continuous glucose monitors, with data managed through Diabeloop's YourLoops cloud platform and downloadable to Glooko.
ViCentra generates revenue from a Starter Kit bundle (two pumps and one handset) and high-frequency recurring consumables, including 200-unit insulin cartridges and 6mm or 9mm soft-cannula infusion sets replaced every 3 days, plus body and pump patches. The company sells exclusively through healthcare-provider prescriptions, supported by certified trainers and local medical device distributors (Mediq, TK-Pharma in Netherlands and Germany; Spezimed in Germany). Pricing is reimbursement-driven and varies by jurisdiction; Kaleido is covered by all Dutch health insurers and is eligible for reimbursement in Germany and France. The installed base grew to over 4,000 users in 2025 (doubled year-over-year), and ViCentra is preparing for U.S. market entry with an FDA filing targeted for early 2026.
ViCentra has raised approximately $200 million in total funding across a $74M Series C (December 2021, led by Partners in Equity) and a $98M Series D (initial $85M close September 2025 led by Innovation Industries, with a $13M second close in January 2026). The company employs over 200 people from 30+ nationalities and is scaling manufacturing capacity more than threefold via a partnership with Phillips Medisize to support 17,000+ users. Senior leadership includes CEO Tom Arnold (ex-Medtronic, Boston Scientific), CFO Leo Toole, CTO and co-founder Tim Oakes, and recently hired commercial leaders Karen Baxter (SVP Sales Europe, ex-Dexcom), Jay Little (VP Strategy, ex-Medtronic), and Reman McDonagh (VP Global Marketing, ex-Insulet/Medtronic/Roche/Cellnovo).
ViCentra firmographics
Firmographics- Name
- ViCentra
- Legal name
- ViCentra B.V.
- Website
- https://hellokaleido.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- ViCentra is a Utrecht-based medical device company that designs and commercializes the Kaleido compact, customizable insulin patch pump system for adults with Type 1 diabetes, integrating Diabeloop hybrid closed-loop algorithms and Dexcom CGM, sold via healthcare-provider prescriptions across Germany, Netherlands, and France with U.S. entry pending FDA approval.
- Ownership category
- akta.pro rank
ViCentra industry classification
Industry- Product category
- Insulin Patch Pumps / Diabetes Management Devices
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
- akta.pro primary industry
- Patch Pumps & Wearable Insulin Delivery (HLAHAHAC)
- akta.pro secondary industries
- Automated Insulin Delivery (AID) / Closed-Loop Systems (HLAHAHAF), Infusion Sets, Catheters & Pump Consumables (HLAHAIAH), Diabetes Care Device Accessories & Adhesives (Sensors/Pump Supplies) (HLAHAHAL)
Keywords
Where ViCentra is headquartered
LocationHeadquarters
- HQ city
- Utrecht
- HQ country
- Netherlands
- HQ region
- Europe
Offices1 record
Markets served
ViCentra business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations
Revenue model
- Insulin Pump Hardware Sales: ViCentra generates revenue from the sale of reusable Kaleido insulin pumps that have a 4-year lifespan and come with a warranty. The Starter Kit includes two pumps and one handset.
- Consumables: Recurring revenue from consumables including insulin cartridges (200-unit capacity, replace every 3 days), infusion sets (6mm or 9mm soft cannulas), and pump/body patches. Users purchase Top-Up Kits for additional supplies.
- Insurance Reimbursement: Kaleido is covered by health insurance in the Netherlands and is eligible for reimbursement in Germany and France through local healthcare systems and distributors.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Multi-year contract | Kaleido Starter Kit with reusable pump and handset |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
ViCentra product offering
Product offeringCore offering
ViCentra designs, manufactures, and sells the Kaleido insulin patch pump system for adults with Type 1 diabetes. The reusable pump (50x35x12.5mm, 19g, 4-year warranty, IP68 waterproof) can be worn as a body patch or carried in a pocket via 5/30cm tubing and is available in 10 color combinations. The offering spans the stand-alone pump with Kaleido handset, the Hybrid Closed Loop system integrating Diabeloop's DBLG1/DBLG2 self-learning algorithms with Dexcom G6/G7 CGM, recurring consumables (200-unit cartridges and 6/9mm infusion sets replaced every 3 days), and the Kaleido Starter Kit bundle. Distribution flows through healthcare provider prescriptions, certified trainers, and local medical device distributors in Europe with health insurance reimbursement coverage.
Product overview
ViCentra's Kaleido is a modular insulin patch pump ecosystem consisting of the Kaleido insulin pump (core device), optional Hybrid Closed Loop add-ons (DBLG1 and DBLG2 algorithms with Dexcom CGM integration), a dedicated Kaleido handset for stand-alone use, consumables (cartridges, infusion sets, patches), and a Starter Kit bundle. The system is distinguished by its compact size, customizable color options, and flexible wear options (as patch or pocket pump with tubing). The DBLG1/DGBL2 algorithms provide AI-powered automated insulin delivery, while the standalone handset includes a bolus calculator and data sync capabilities.
Differentiator
Problem solved
Functional benefit
Brands
- Kaleido: The Kaleido insulin patch pump system - a flexible, discreet insulin delivery device available as both standalone pump and Hybrid Closed Loop system integrated with Diabeloop's DBLG1 and DBLG2 algorithms and Dexcom CGM.
Products and services
- Kaleido Insulin Patch Pump System A compact, customizable insulin patch pump system for adults with Type 1 diabetes. Features a reusable pump with 4-year warranty, waterproof (IP68) design for 1 hour at 1.5m, 10 color combinations, dual-wear flexibility (5/30cm tubing for body patch or pocket use), and 0.05-unit pulse technology for precise dosing.
- Kaleido Hybrid Closed Loop System (DBLG1 with Dexcom G6) Automated insulin delivery system combining the Kaleido pump with Diabeloop's DBLG1 self-learning algorithm and the Dexcom G6 CGM. Continuously monitors glucose and adjusts insulin delivery in real-time. Clinical evidence shows Time in Range improved from 57.3% to 68.8%.
- Kaleido with DBLG2 and Dexcom G7 Next-generation smartphone-controlled Hybrid Closed Loop system combining the Kaleido pump with Diabeloop's DBLG2 self-learning algorithm and Dexcom G7 CGM sensor.
- Kaleido Handset Reusable dedicated controller for the Kaleido stand-alone pump. Features bolus calculator (Kaleidoculator), 7 basal rate profiles, data upload to Glooko, and 1.5–2 day battery life per charge.
- Kaleido Consumables Recurring-use consumables for the Kaleido pump system: 200-unit insulin cartridges with 5cm or 30cm tubing, 90-degree Teflon soft cannula infusion sets (6mm or 9mm), and body/pump patches, replaced every 3 days. Top-Up Kits are available for additional supplies.
- Kaleido Starter Kit Starter package containing two reusable Kaleido pumps (each with a 4-year warranty), one Kaleido handset, and comprehensive training and technical support.
Quantifiable outcome
- Time in Range increased from 57.3% to 68.8% after using Kaleido Hybrid Closed Loop system
- +3 more outcomes
Companies that use ViCentra
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
ViCentra technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration6 records
AI capability2 records
Feature5 records
ViCentra partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- Phillips MedisizecoreContract manufacturing partnership for commercial-scale production of Kaleido consumables. Phillips Medisize manufactures infusion sets and patches, enabling ViCentra to more than triple production capacity to support over 17,000 users.
- DiabeloopcoreStrategic technology partnership for hybrid closed loop insulin delivery. Kaleido integrates with Diabeloop's DBLG1 and DBLG2 self-learning algorithms for automated insulin dosing decisions based on real-time CGM data. The partnership enables the Kaleido Hybrid Closed Loop system combining pump, CGM, and algorithm.
- DexcomcoreTechnology integration for continuous glucose monitoring. Kaleido HCL system uses Dexcom G6 sensor for real-time glucose readings, with DBLG2 also supporting Dexcom G7. Integration enables automated insulin delivery adjustments.
- JDRFminorCollaboration with JDRF (Juvenile Diabetes Research Foundation) to support diabetes research and advocacy. ViCentra works with JDRF to develop ideas and improve outcomes for people with Type 1 diabetes.
- TK-PharmacoreDistributor for Kaleido products in Germany and Netherlands. Handles product availability and logistics for patients in these markets.
- MediqcoreDistributor for Kaleido products in Germany and Netherlands. Provides product distribution and availability through local healthcare channels.
- SpezimedcoreDistributor for Kaleido products in Germany. Enables local product availability and access for German patients.
Scale indicators7 records
Recent moves9 records
Expansion highlights6 records
ViCentra competitors and assessment
Company assessmentDirect peers
- Insulet Corporation: Maker of the Omnipod tubeless patch pump, the most direct competitor to Kaleido in disposable patch insulin delivery. Both companies target the same Type 1 diabetes patient pool with wearable, discreet pumps and compete for the same hybrid closed loop and smartphone-control positioning.
- Tandem Diabetes Care: Maker of the t:slim X2 insulin pump with Control-IQ AID algorithm integrated with Dexcom CGM. Directly competes with Kaleido in the AID category, particularly for patients seeking smartphone-controlled automated insulin delivery, though Tandem's pump is tubed rather than patch-style.
- Ypsomed: European-based developer and manufacturer of patch insulin pumps (mylife Loop) using a tubeless patch form factor and integration with CamDiab AID and Dexcom CGM. Closely comparable to Kaleido in product format, target market (Type 1 diabetes), and European commercial geography.
Broad incumbents
- Medtronic: Sells the MiniMed 780G insulin pump, an established AID competitor integrated with its own Guardian CGM. Overlaps with ViCentra in the automated insulin delivery category and dominates the broader diabetes hardware market, including pediatric indications and U.S. distribution depth.
- Roche Diabetes Care: Diversified diabetes device and diagnostics incumbent (Accu-Chek pumps, meters, digital tools). Competes more broadly in diabetes management rather than directly head-to-head in patch pumps, but overlaps in European reimbursement channels and target patient population.
- Dexcom: Leading continuous glucose monitor (G6, G7) maker and a strategic partner of ViCentra through the Kaleido HCL system. Comparable as a core diabetes technology provider, although Dexcom's primary focus is CGM rather than insulin delivery.
Others
- Abbott Diabetes Care: Competes in adjacent diabetes technology via FreeStyle Libre CGM, increasingly paired with AID systems. While not an insulin pump maker, it competes for the same diabetes technology budget and increasingly enables do-it-yourself AID solutions that compete with commercial patch pumps.
- Diabeloop: Strategic partner of ViCentra providing the DBLG1 and DBLG2 self-learning AID algorithms integrated with Kaleido. Comparable as a diabetes AID technology provider, though its commercial model focuses on algorithm licensing rather than pump hardware.
- CamDiab: Developer of the CamAPS FX closed-loop algorithm used in AID systems including Ypsomed's mylife Loop. Comparable to Diabeloop as an algorithm partner in the AID ecosystem, relevant given the importance of AID algorithms to patch pump value propositions.
Regional players
- Sooil Development (Dana Diabecare): South Korea-based manufacturer of patch-style insulin pumps (Dana Diabecare) integrating with CGM systems. Comparable to ViCentra in patch form factor and AID positioning but focused primarily on Asian markets rather than competing directly in Europe or the U.S.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
ViCentra social profiles
Digital presenceViCentra compliance and trust
Trust signalCompliance3 records
ViCentra financial estimates
Financial estimateRevenue estimate
Valuation estimate
ViCentra leadership team
Management profileNumber of profiles
Profiles16 records
ViCentra funding detail
Funding detailFunding overview
Funding rounds6 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ViCentra M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ViCentra
What does ViCentra do?
ViCentra designs, manufactures, and sells the Kaleido insulin patch pump system for adults with Type 1 diabetes. The reusable pump (50x35x12.5mm, 19g, 4-year warranty, IP68 waterproof) can be worn as a body patch or carried in a pocket via 5/30cm tubing and is available in 10 color combinations. The offering spans the stand-alone pump with Kaleido handset, the Hybrid Closed Loop system integrating Diabeloop's DBLG1/DBLG2 self-learning algorithms with Dexcom G6/G7 CGM, recurring consumables (200-unit cartridges and 6/9mm infusion sets replaced every 3 days), and the Kaleido Starter Kit bundle. Distribution flows through healthcare provider prescriptions, certified trainers, and local medical device distributors in Europe with health insurance reimbursement coverage.
Is ViCentra a public or private company?
ViCentra is a private company. It is classified as venture growth investor backed and is currently operating.
When was ViCentra founded?
ViCentra was founded in 2013. It employs 101 to 250 people.
Where is ViCentra based?
ViCentra is headquartered in Utrecht, Netherlands, in the Europe region.
How does ViCentra make money?
Three revenue lines are on record. Insulin Pump Hardware Sales are the primary driver. The others are consumables and insurance Reimbursement.
Who are ViCentra's main competitors?
Direct peers on record are Insulet Corporation, Tandem Diabetes Care and Ypsomed. Broad incumbents are Medtronic, Roche Diabetes Care and Dexcom. Others are Abbott Diabetes Care, Diabeloop and CamDiab. Sooil Development (Dana Diabecare) is listed as a regional player.
Does ViCentra have an API?
No public API is recorded for ViCentra.
What industry is ViCentra in?
ViCentra's product category is Insulin Patch Pumps / Diabetes Management Devices. Its primary akta.pro industry code is HLAHAHAC, Patch Pumps & Wearable Insulin Delivery, with a secondary code of HLAHAHAF, Automated Insulin Delivery (AID) / Closed-Loop Systems. Its NAICS code is 339113 and its SIC code is 5047.